Home » Topics » BioWorld Science, Dermatologic

BioWorld Science, Dermatologic
RSS

First patient dosed in the phase I/II trial of KB-103

May 11, 2018

FDA approves IND for female hair loss trial of Histogen's HSC-660

May 7, 2018

Lilly initiates phase III study of mirikizumab in moderate to severe plaque psoriasis

May 7, 2018

Azitra raises new financing to advance pipeline

May 4, 2018

MOR-106 moves into phase II development for atopic dermatitis with IGUANA trial

May 3, 2018

Exicure reports phase I data on AST-005 in plaque psoriasis

May 2, 2018

AbbVie submits European MAA for risankizumab in moderate to severe plaque psoriasis

May 2, 2018

EMA committee hands down positive opinion for Cimzia in moderate to severe plaque psoriasis

April 30, 2018

AbbVie submits BLA to the FDA for risankizumab in moderate to severe plaque psoriasis

April 26, 2018

KB-103 receives orphan medicinal product designation in Europe

April 20, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 30, 2026.
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
With improved technologies, biomarkers, failed drugs may come into their own
BioWorld
At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 24, 2026